BIIB vs LGN · P/E 21, rev $9.89B vs rev $2.55B
Biogen Inc (BIIB) versus Legence Corp. Class A Common stock (LGN) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Legence Corp. Class A Common stock (LGN) is a engineering & construction company listed on NASDAQ.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported LGN revenue for 2025-12-31 was $2.55B. Net income was -$59.8M. Revenue was up 21.5% from 2024-12-31 to 2025-12-31. LGN currently screens at market cap $14.66B.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. LGN currently screens at market cap $14.66B.
Not investment advice. Open the BIIB and LGN stock pages for the full models.
Not investment advice.